Premium
Treatment of advanced ovarian cancer with combination chemotherapy using cyclophosphamide, adriamycin and cis‐platinum
Author(s) -
MILSTED R.,
SANGSTER G.,
KAYE S.,
CALMAN K.,
CORDINER J.,
SOUTTER W.,
BARR W.,
CUNNINGHAM D.,
SOUKOP M.,
KENNEDY J.,
McEWAN H.
Publication year - 1984
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1984.tb03711.x
Subject(s) - laparotomy , medicine , cyclophosphamide , regimen , chemotherapy , ovarian cancer , surgery , context (archaeology) , disease , combination chemotherapy , oncology , cancer , paleontology , biology
Summary. Fifty‐four patients with advanced ovarian cancer have been treated with combination chemotherapy using cyclophosphamide, adriamycin and cis‐platinum. The toxicity of the regimen was manageable but few patients were prepared to tolerate more than 6 months of treatment. Those in complete clinical remission at that time were offered second‐look laparotomy and if apparently free of disease, therapy was discontinued. Forty‐seven patients could be assessed of whom 33 had had no previous therapy. Twenty‐two of these were clinically free of disease after completion of chemotherapy of whom 12 had no detectable disease at second‐look laparotomy. Of 14 patients who had failed previous therapy only one remains clinically free of disease. The results in the untreated patients demonstrate the primary importance of bulk reduction at initial laparotomy. The use of the regimen in patients who have failed on previous treatment or in patients with bulk disease seems to be palliative and the toxicity should be assessed in this context.